- Home
- ADEA vs KNSA Comparison
ADEA vs KNSA Comparison
Compare ADEA & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADEA | KNSA |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.5B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ADEA | KNSA |
|---|---|---|
| Price | $30.98 | $59.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $31.00 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.7M | 802.7K |
| Earning Date | 05-04-2026 | 04-28-2026 |
| Dividend Yield | ★ 0.65% | N/A |
| EPS Growth | 73.68 | ★ 225.00 |
| EPS | 0.20 | ★ 0.27 |
| Revenue | $443,386,000.00 | ★ $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $5.63 | $17.87 |
| P/E Ratio | ★ $161.15 | $215.19 |
| Revenue Growth | 17.91 | ★ 60.09 |
| 52 Week Low | $11.61 | $25.71 |
| 52 Week High | $34.34 | $59.75 |
Technical Indicators
Market Signals| Indicator | ADEA | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 56.56 | 72.13 |
| Support Level | $16.07 | $40.67 |
| Resistance Level | $34.34 | N/A |
| Average True Range (ATR) | 1.87 | 2.45 |
| MACD | -0.24 | 0.95 |
| Stochastic Oscillator | 54.86 | 97.30 |
Price Performance
Historical ComparisonAbout ADEA Adeia Inc.
Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.